Cargando…
Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
Many therapeutic antibodies (Abs) and mRNA vaccines, both targeting SARS-CoV-2 spike protein (S-protein), have been developed and approved in order to combat the ongoing COVID-19 pandemic. In consideration of these developments, a common concern has been the potential for Ab-dependent enhancement (A...
Autores principales: | Shimizu, Jun, Sasaki, Tadahiro, Koketsu, Ritsuko, Morita, Ryo, Yoshimura, Yuka, Murakami, Ami, Saito, Yua, Kusunoki, Toshie, Samune, Yoshihiro, Nakayama, Emi E., Miyazaki, Kazuo, Shioda, Tatsuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481526/ https://www.ncbi.nlm.nih.gov/pubmed/36114224 http://dx.doi.org/10.1038/s41598-022-19993-w |
Ejemplares similares
-
Author Correction: Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
por: Shimizu, Jun, et al.
Publicado: (2023) -
The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production
por: Shimizu, Jun, et al.
Publicado: (2021) -
Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
por: Boudreau, Carolyn M., et al.
Publicado: (2019) -
Human FcR Polymorphism and Disease
por: Li, Xinrui, et al.
Publicado: (2014) -
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)